Life Sciences Point-of-Care Testing Solutions sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Life Sciences Point-of-Care Testing Solutions
1.1 - About Life Sciences Point-of-Care Testing Solutions sector
Companies in this category design, manufacture, and integrate near‑patient diagnostic systems that deliver lab-quality results within minutes at clinical settings. Life Sciences Point-of-Care Testing Solutions providers enable rapid screening, triage, and monitoring by combining portable analyzers, disposable test cartridges, and connected software. Their value centers on accelerating clinical decision-making, reducing reliance on centralized labs, and expanding access to diagnostics across distributed care sites.
Vendors typically offer lateral flow immunoassays for infectious disease and cardiac markers, molecular point‑of‑care NAAT platforms with sample‑to‑answer cartridges, compact immunoassay analyzers for quantitative testing, and handheld digital readers that standardize interpretation. They augment devices with CLIA‑waived test kits, quality control materials, calibration tools, and device connectivity that integrates with LIS/EMR systems, supports remote monitoring, and enables automated result reporting to clinicians and public health registries.
Primary customers include hospitals and health systems, urgent care and retail clinics, and physician office laboratories. These solutions shorten time‑to‑diagnosis, improve throughput in triage workflows, and enable care delivery in resource‑limited settings. Buyers also see better test accuracy through standardized readers, reduced total cost by minimizing send‑outs to central labs, and enhanced compliance via electronic reporting and integration with existing clinical information systems.
2. Buyers in the Life Sciences Point-of-Care Testing Solutions sector
2.1 Top strategic acquirers of Life Sciences Point-of-Care Testing Solutions companies
EchoNous
- Description: Provider of AI-driven point-of-care ultrasound solutions. EchoNous develops the Kosmos family of portable probes, tablets and bundled systems that deliver high-resolution, real-time imaging for musculoskeletal, cardiovascular, vascular access and other clinical applications, improving procedural guidance, diagnostic speed and patient outcomes.
- Key Products:
- Kosmos Hand-Carried Ultrasound: Cart-benchmarked
- AI-automated handheld device offering Tissue Doppler Imaging plus Continuous and Pulsed Wave Doppler in an ultraportable form for high-quality bedside imaging
- Kosmos AI Portfolio: Deep-learning based platform that continually evolves to automate image interpretation and resolve everyday healthcare challenges, boosting diagnostic accuracy and efficiency
- Kosmos Software Solutions: Workflow software and partner integrations that streamline ultrasound data management and clinical processes across care settings
- EchoNous Bladder: All-electronic, non-mechanical bladder scanner engineered for high durability and reliable volume measurement, reducing catheterization risks and enhancing patient care.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Life Sciences Point-of-Care Testing Solutions sector
M&A buyer group 1: In Vitro Diagnostics
OPKO Health
- Type: N/A
- Employees: ●●●●●
- Description: Provider of next-generation healthcare solutions, OPKO Health develops and markets therapies for serious diseases worldwide, leveraging global operating businesses and partnerships to create novel multispecific medicines for cancer and infectious diseases.
- Key Products:
- Marketed Therapies: Portfolio of approved treatments distributed worldwide through commercial partnerships, providing patients with established therapeutic options for serious diseases across multiple global markets
- Multispecific Cancer Medicines (in development): Novel multispecific drug candidates designed to target multiple cancer pathways simultaneously, aiming to improve efficacy and patient outcomes in oncology
- Multispecific Infectious Disease Medicines (in development): Next-generation therapeutics engineered to act on multiple targets within pathogens, pursuing enhanced effectiveness against complex infectious diseases
- Global Operating Businesses: Integrated healthcare operations in the U.S.
- Mexico
- Chile
- Spain
- Ireland and Israel that generate stable profits and support R&D, including manufacturing, distribution and commercialization capabilities for OPKO’s therapies.
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Life Sciences Point-of-Care Testing Solutions sector
3.1 - Buyout funds in the Life Sciences Point-of-Care Testing Solutions sector
2.2 - Strategic buyer groups for Life Sciences Point-of-Care Testing Solutions sector
4 - Top valuation comps for Life Sciences Point-of-Care Testing Solutions companies
4.2 - Public trading comparable groups for Life Sciences Point-of-Care Testing Solutions sector
Valuation benchmark group 1: Clinical and Molecular Diagnostics Companies
Labcorp
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of comprehensive clinical laboratory and drug development services, harnessing science for human good with a wide range of diagnostic tests, specialty testing services, and research support globally.
- Key Products:
- Diagnostic Testing: Wide range of diagnostic tests for various conditions
- Specialty Testing: Advanced gene-based and esoteric testing
- Drug Development Services: Comprehensive services for drug development and clinical trials
- Health Screenings: Wellness, pediatric, COVID-19 antibody testing
- Labcorp OnDemand: At-home test kits and monitoring solutions